MHRA to Require Briefing Documents for Scientific Advice

MHRA has rewritten the rules for asking it a question. An update to its guidance, "Medicines: get scientific advice from the MHRA", posted 14 August 2026, tells sponsors to submit a final briefing document and their proposed questions at the point of requesting Scientific Advice — not, as before, at some point after the request goes in. From September 2026, that submission is mandatory for every request, not optional best practice.

What sponsors have to submit, and when

The mechanics of MHRA Scientific Advice have not changed: sponsors can ask for written advice alone or for a meeting, and can scope the request narrowly, to a single development programme, or more broadly, to questions that span a product's lifecycle. What has changed is the sequencing. Under the revised guidance, the briefing document — the paper that lays out the sponsor's data, position, and specific questions — and the list of questions themselves have to be finished and submitted when the request is made, rather than developed or finalized in the run-up to the meeting. MHRA has also expanded what it expects a briefing document to contain: a clearly stated company position on the issue, the scientific justification behind that position, and an explanation of how the request aligns with relevant existing MHRA guidance.

Why the timing is the change that matters

A scientific-advice meeting is only as useful as the material a reviewer has had time to read. Requiring the finished briefing document at request stage — rather than accepting a placeholder request followed by a document that lands closer to the meeting date — gives MHRA's assessors a fixed, known-complete package to prepare against from day one. It also removes an ambiguity that has shaped how sponsors plan their internal timelines: teams no longer have a natural buffer between requesting a slot and finishing the underlying analysis, which pushes the real deadline for pivotal data and internal sign-off earlier in a programme's calendar than some sponsors may have been assuming.

How this sits alongside MHRA's other advice routes

The updated guidance covers MHRA-only Scientific Advice as well as Integrated Scientific Advice, the joint route with the National Institute for Health and Care Excellence that lets a sponsor discuss clinical study design against both regulatory and health-technology-assessment requirements in a single meeting, then receive separate advice documents from each body afterward. Fees apply to both routes: since 1 February 2025, new requests must be paid no later than three weeks before any scheduled meeting date, though UK-based small and medium-sized enterprises with approved SME status remain exempt. None of that machinery changes here — only what has to be in hand, and when, before MHRA will engage with the request at all. It is a narrower, process-level companion to the faster review timelines MHRA has been rolling out elsewhere this year: speed on the regulator's side is only as useful as a complete submission on the sponsor's.

What is not yet in force

The mandatory requirement does not take effect until September 2026; the 14 August update is the guidance change that announces and defines it, not the compliance date itself. MHRA has not published a specific day in September on which the requirement becomes binding, nor has it described a transition or grace period for requests already in progress. Sponsors planning a Scientific Advice request in the coming weeks should treat the finished-briefing-document standard as the one to meet now, rather than wait for a hard cutover date that MHRA's own guidance does not yet spell out.